IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Kintegral Advisory LLC

Kintegral Advisory LLC lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 4.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,510 shares of the company’s stock after selling 256 shares during the period. Kintegral Advisory LLC’s holdings in IDEXX Laboratories were worth $2,278,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Chicago Partners Investment Group LLC raised its position in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after acquiring an additional 96 shares during the last quarter. National Pension Service raised its position in shares of IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after purchasing an additional 12,647 shares during the last quarter. Insight Wealth Strategies LLC raised its position in shares of IDEXX Laboratories by 230.5% during the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company’s stock worth $4,174,000 after purchasing an additional 7,041 shares during the last quarter. Larson Financial Group LLC lifted its stake in IDEXX Laboratories by 17,238.5% in the 3rd quarter. Larson Financial Group LLC now owns 2,254 shares of the company’s stock valued at $1,139,000 after buying an additional 2,241 shares in the last quarter. Finally, Quest Partners LLC grew its holdings in IDEXX Laboratories by 4,059.4% during the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after buying an additional 2,801 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

IDEXX Laboratories stock opened at $452.77 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The company has a market cap of $37.08 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 3.41 and a beta of 1.37. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm has a 50 day moving average price of $431.92 and a 200 day moving average price of $452.28.

Insider Activity

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Sophie V. Vandebroek sold 344 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the sale, the director now directly owns 905 shares of the company’s stock, valued at $380,498.20. The trade was a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock valued at $6,161,276 in the last ninety days. Company insiders own 2.11% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Piper Sandler upped their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Bank of America raised their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Finally, Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Four research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $533.75.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.